Int J Med Sci 2020; 17(7):892-902. doi:10.7150/ijms.43079
Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges
1. Department of Infectious Disease, Xiangya Hospital, Central South University, Changsha 410008, China
2. Department of Microbiology, School of Basic Medical Science, Central South University, Changsha 410078, China
Zeng H, Li L, Hou Z, Zhang Y, Tang Z, Liu S. Direct-acting Antiviral in the Treatment of Chronic Hepatitis C: Bonuses and Challenges. Int J Med Sci 2020; 17(7):892-902. doi:10.7150/ijms.43079. Available from http://www.medsci.org/v17p0892.htm
Owing to the rapid development and wide clinical application of direct acting antiviral (DAA) drugs in the treatment of hepatitis C virus (HCV) infection, the era of interferon-based therapy has almost come to an end. Cumulative studies show that DAA therapy renders high cure efficiency (>90%) and good safety profile, and may even bring some unexpected benefits to the patients. However, some issues of concern arise, one of which is the resistance mutation of HCV genome leading to failure of treatment. With the aim of providing some meaningful references for the treatment of chronic hepatitis C (CHC), this article summarizes the research progress on benefits of DAA accompanied by viral clearance in the treatment of chronic hepatitis and the drug resistance.
Keywords: hepatitis C virus (HCV), direct acting antiviral (DAA), sustained virological response (SVR), resistance-associated substitutions (RAS)